GlassScriptPhysician profile
Jamie Bird
NPI 1568902922
$2,771.31
in general payments reported to CMS, 2019-2025
30 companies · $540 in 2025
The $540 reported for 2025 was more than what 76% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $297 · 2022: $338 · 2023: $531 · 2024: $1,067 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.93 | 2021-2025 | |
| Novo Nordisk INC | $379.92 | 2023-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $311.94 | 2021-2025 | Farxiga, Airsupra, Andexxa |
| Exact Sciences Corporation | $173.82 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $137.42 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $118.06 | 2023-2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $97.83 | 2022-2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $96.06 | 2022-2024 | Camzyos |
| Vanda Pharmaceuticals INC. | $77.77 | 2024 | Fanapt |
| Amgen INC. | $75.81 | 2023-2024 | Repatha, Otezla, Enbrel |
| Janssen Pharmaceuticals, INC | $73.34 | 2021-2023 | Xarelto |
| Pfizer INC. | $71.01 | 2021-2025 | |
| Axsome Therapeutics, INC. | $65.72 | 2025 | Auvelity |
| Boston Scientific Corporation | $61.44 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Smith+Nephew, INC. | $61.10 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.65 | 2021-2022 | |
| Dexcom, INC. | $48.61 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $44.24 | 2024 | |
| Irhythm Technologies, INC. | $42.37 | 2024 | Zio Xt Patch, Zio Monitor |
| Kci USA, INC. | $41.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.19 | 2023-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.16 | 2021-2025 | Xifaxan |
| Lundbeck LLC | $30.90 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $25.11 | 2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.50 | 2024 | Caplyta |
| Antares Pharma, INC. | $22.36 | 2023 | Nocdurna, Tlando, Xyosted |
| Corcept Therapeutics | $21.10 | 2025 | Korlym |
| Mylan Specialty L.P. | $19.35 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $19.24 | 2022 | |
| Medtronic, INC. | $17.39 | 2025 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.